COMMUNIQUÉS West-GlobeNewswire

Marie-Hélène Laramée, présidente-directrice générale de la Fondation du CUSM, nommée au conseil d’administration de l’Association canadienne pour l’équité en santé des femmes
12/08/2026
La nomination de Marie-Hélène Laramée renforce la voix du Québec au sein du mouvement national. Son objectif : combler les lacunes en matière de recherche, de soins et de leadership en santé des femmes MONTREAL, 12 août [...]
MUHC Foundation President and CEO Marie-Hélène Laramée appointed to Women’s Health Collective Canada Board of Directors
12/08/2026
Laramée’s appointment strengthens Quebec’s voice in the national movement to close gaps in women’s health research, care, and leadership MONTREAL, Aug. 12, 2026 (GLOBE NEWSWIRE) -- The McGill University Health Centre ( [...]
Solana Company to Release Second Quarter 2026 Operating Results on August 14, 2026
12/08/2026
PHILADELPHIA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed digital asset treasury, infrastructure, and services company providing institutional access to [...]
Bone Biologics Achieves 32-Month Validated Shelf Life for rhNELL-1
12/08/2026
Milestone strengthens manufacturing flexibility and supports pivotal study readiness BURLINGTON, Mass, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, [...]
Reflect Scientific Reports More Than $1.4 Million in Freezer-System Sales to Biopharmaceutical Customers
12/08/2026
OREM, Utah, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (Symbol: RSCF) today announced more than $1.4 million in delivered commercial freezer-system sales to six biopharmaceutical companies during the [...]
Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors
12/08/2026
CONSHOHOCKEN, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated [...]
ADARx Pharmaceuticals Expands Leadership Team with Board and Executive Appointments
12/08/2026
– Ying Huang, Ph.D. appointed to Board of Directors, bringing deep experience spanning executive public biotech leadership, Wall Street and big pharma R&D – – Robert Ackles joins as Chief People Officer, bringing [...]
Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates
12/08/2026
Received FDA clearance of IND application for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Advancing IND-enabling studies for potential first-in-class multi-specific, masked T cell engager programs [...]
BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights
12/08/2026
Record s econd q uarter 2026 r evenue increased 35% t o $17. 1 m illion, compared with Q2 2025 Adjusted EBITDA more than doubled year-over-year to $3.5 million, with margin expanding to 20% Remaining performance [...]
PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results
12/08/2026
FDA Accepted D-PLEX₁₀₀ NDA with Priority Review; PDUFA Goal Date of November 28, 2026, Approximately One Quarter Ahead of Previously Communicated Guidance Exclusive U.S. and Canada Commercialization Partnership with [...]
Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates
12/08/2026
Randomized Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC) ongoing, with results expected in 1H 2027; potential registration trial expected in 2027 once recommended dose regimen has been established [...]
Altimmune Announces Second Quarter 2026 Financial Results and Business Update
12/08/2026
Initiated global PERFORMA Phase 3 trial in MASH Reported positive topline data from RECLAIM Phase 2 trial in AUD Completed patient enrollment in RESTORE Phase 2 trial in ALD $519 million in cash, cash equivalents and [...]
TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
12/08/2026
First patient dosed in Phase 3 ALLOHA-2™ study; topline readout expected mid-2028 Shared positive initial data from Cohort C of Phase 1 ALLOHA™ study, validating internal commercial-ready manufacturing process Cash and [...]
Kamada Announces Planned Transition of Chief Financial Officer
12/08/2026
REHOVOT, Israel, and HOBOKEN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious [...]
Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights
12/08/2026
Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026 Two candidates nominated for development in Acumen’s [...]
Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights
12/08/2026
Finalized SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 in support of accelerated approval pathway; topline data expected in second half of 2027 Initiated SUNRISE-FA 2 with first patient enrolled [...]
Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update
12/08/2026
– Breakthrough results from V012 dialysis access Phase 3 study, where ATEV was observed to outperform AV fistula; supplemental Biologic License Application (sBLA) for dialysis access to be filed with the Food and Drug [...]
Attralus Has Been Granted U.S. FDA Fast Track Designation for Zamubafusp Alfa (AT-02) for the Treatment of AL Amyloidosis
12/08/2026
NAPLES, Fla., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today announced [...]
Persephone Biosciences Publishes Largest U.S. Clinical Study of an Infant Synbiotic in Pediatric Research, Expanding Clinical Evidence for Its Infant Synbiotics
12/08/2026
Publication reports results from the largest U.S. randomized trial evaluating a synergistic Bifidobacterium-HMO synbiotic in infants and toddlers, demonstrating safety, successful gut colonization and biologically [...]

Pages